<DOC>
	<DOCNO>NCT01077544</DOCNO>
	<brief_summary>This study ass pharmacokinetics nilotinib Ph+ CML pediatric patient newly diagnose resistant intolerant imatinib dasatinib refractory relapse Ph+ ALL compare adult population . It also evaluate safety activity nilotinib secondary objective .</brief_summary>
	<brief_title>A Pharmacokinetic ( PK ) Study Nilotinib Pediatric Patients With Philadelphia Chromosome-positive ( Ph+ ) Chronic Myelogenous Leukemia ( CML ) Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Must one following : newly diagnose CP Ph+CML , CP AP resistant/ intolerant imatinib and/or dasatinib , Ph+ ALL either relapse refractory standard therapy adequate renal , hepatic pancreatic function patient receive therapy strong CYP3A4 inhibitor and/or inducer treatment stop change different medication least 14 day prior start study drug patient receive therapy medication know risk possible risk prolong QT interval treatment either discontinue switched different medication prior start study drug . gastrointestinal impairment disease may interfere drug absorption liver , pancreatic severe renal disease unrelated disease study impair cardiac function patient receive dasatinib within 3 day start study drug patient receive imatinib within 5 day start study drug patient receive hydroxyurea corticosteroid discontinue least 1 week initiation nilotinib patient receive hematopoietic growth factor within 7 day start study drug Pegfilgrastim ( NeulastaÂ® ) within 14 day start study drug patient Stem Cell Transplant ( SCT ) Rescue without TBI : Evidence active graft vs. host disease &lt; 3 month since SCT Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Ph+ CML</keyword>
	<keyword>Ph+ ALL</keyword>
	<keyword>pediatric</keyword>
	<keyword>nilotinib</keyword>
	<keyword>imatinib</keyword>
	<keyword>chronic phase</keyword>
	<keyword>accelerate phase</keyword>
	<keyword>newly diagnose Ph+ CML</keyword>
	<keyword>dasatinib</keyword>
</DOC>